Renaissance Technologies
OCUL icon

Renaissance Technologies’s Ocular Therapeutix OCUL Stock Holding History

Renaissance Technologies’s Portfolio OCUL Stock Details OCUL Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q2 		$3.72M Sell
378,754
-769,228
-67% -$6.97M 0.01% 1621
2026
Q1 		$9.72M Buy
1,147,982
+356,782
+45% +$3.4M 0.02% 984
2025
Q4 		$9.61M Buy
+791,200
New +$9.61M 0.01% 935
2025
Q3 		– Sell
-410,048
Closed -$3.81M – 3782
2025
Q2 		$3.81M Sell
410,048
-43,952
-10% -$344K 0.01% 1693
2025
Q1 		$3.33M Buy
+454,000
New +$3.49M 0.01% 1687
2024
Q2 		– Sell
-29,700
Closed -$270K – 3830
2024
Q1 		$270K Buy
+29,700
New +$211K ﹤0.01% 3127
2023
Q4 		– Sell
-125,200
Closed -$393K – 4010
2023
Q3 		$393K Buy
125,200
+100,307
+403% +$410K ﹤0.01% 2823
2023
Q2 		$128K Sell
24,893
-46,300
-65% -$275K ﹤0.01% 3413
2023
Q1 		$375K Sell
71,193
-222,800
-76% -$1.06M ﹤0.01% 3015
2022
Q4 		$826K Buy
293,993
+279,200
+1,887% +$924K ﹤0.01% 2646
2022
Q3 		$61K Sell
14,793
-366,707
-96% -$1.85M ﹤0.01% 3706
2022
Q2 		$1.53M Sell
381,500
-129,305
-25% -$488K ﹤0.01% 2386
2022
Q1 		$2.53M Buy
510,805
+430,705
+538% +$2.39M ﹤0.01% 2056
2021
Q4 		$558K Sell
80,100
-166,100
-67% -$1.29M ﹤0.01% 3023
2021
Q3 		$2.46M Sell
246,200
-80,922
-25% -$909K ﹤0.01% 1937
2021
Q2 		$4.64M Buy
327,122
+277,222
+556% +$4.21M 0.01% 1683
2021
Q1 		$819K Sell
49,900
-284,166
-85% -$5.47M ﹤0.01% 2697
2020
Q4 		$6.92M Buy
+334,066
New +$4.96M 0.01% 1395
2017
Q2 		– Sell
-88,900
Closed -$825K – 3317
2017
Q1 		$825K Sell
88,900
-56,200
-39% -$468K ﹤0.01% 2607
2016
Q4 		$1.21M Buy
+145,100
New +$1.13M ﹤0.01% 2464
2016
Q3 		– Sell
-47,300
Closed -$234K – 3450
2016
Q2 		$234K Buy
+47,300
New +$469K ﹤0.01% 3005
2015
Q3 		– Sell
-10,992
Closed -$231K – 3299
2015
Q2 		$231K Buy
+10,992
New +$272K ﹤0.01% 2950

Other funds holding OCUL

Fidelity Investments
Fidelity Investments Boston, Massachusetts $2.3T AUM 54.33% 1-Year Est. Return
DTC
Deep Track Capital Greenwich, Connecticut $6.87B AUM 205.24% 1-Year Est. Return
BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
ACA
Avoro Capital Advisors New York $11.1B AUM 207.82% 1-Year Est. Return
SR
Summer Road West Palm Beach, Florida $161M AUM 27.24% 1-Year Est. Return
VA
VR Adviser New York $3.3B AUM 525.74% 1-Year Est. Return
Vanguard Capital Management
Vanguard Capital Management Malvern, Pennsylvania $4.68T AUM
T. Rowe Price Associates
T. Rowe Price Associates Baltimore, Maryland $999B AUM 46.22% 1-Year Est. Return
LGM
Logos Global Management San Francisco, California $2.32B AUM 536.01% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return

Renaissance Technologies's OCUL Position: Q2 2026 in Review

Renaissance Technologies reduced its Ocular Therapeutix (OCUL) stake by 67% in Q2 2026, selling an estimated $6.97M and leaving 378,754 shares worth $3.72M. The position accounts for 0.01% of the portfolio, ranked #1621.

Renaissance Technologies first reported a position in OCUL in Q2 2015 and has held it in 22 quarters since. The position peaked at $9.72M in Q1 2026. 263 funds tracked by Wall St. Rank hold OCUL as of Q2 2026.

  • Renaissance Technologies held 378,754 shares of Ocular Therapeutix worth $3.72M as of Q2 2026.
  • Renaissance Technologies sold 769,228 Ocular Therapeutix shares in Q2 2026, an estimated $6.97M.
  • Ocular Therapeutix made up 0.01% of Renaissance Technologies's portfolio in Q2 2026, its #1621 holding.
  • Renaissance Technologies first reported a position in Ocular Therapeutix in Q2 2015 and has held it in 22 quarters since.
  • Renaissance Technologies's Ocular Therapeutix position peaked at $9.72M in Q1 2026.
  • 263 funds tracked by Wall St. Rank held Ocular Therapeutix as of Q2 2026.

Based on Renaissance Technologies's 13F filing for Q2 2026, filed 13 Aug 2026.